Korean J Hematol 2000; 35(2):
Published online June 30, 2000
© The Korean Society of Hematology
급성 골수성 백혈병 환자에서 Idarubicin/BH-AC 복합관해유도요법의 치료 효과 및 예후 분석
이제중, 정익주, 양덕환, 조상희, 양태영, 박형천, 박무림, 김형준
전남대학교 의과대학 내과학교실
Therapeutic Effect and Prognostic Analysis of Induction Chemotherapy with Idarubicin/BH-AC in Acute Myelogenous Leukemia
BACKGROUND: We have analyzed the outcome and prognostic factors for 61 patients with acute myelogenous leukemia (AML) who were treated with idarubicin(IDA)/N 4-behenoyl-1-β-D-arabinofuranosylcytosine(BH-AC) regimen at Chonnam National University Hospital between April 1994 and December 1998.
METHODS: Fifty-six patients with newly diagnosed AML and 5 patients failed by IDA/ara-C were eligible to analysis. Remission induction chemotherapy consisted of IDA (12 mg/㎡/day IV over 30 minutes on days 1∼3) and BH-AC (age≤40 years : 300 mg/㎡/day IV over 4 hours on days 1∼7 ; age>40 years : 200 mg/㎡/day). After achievement of a complete remission (CR), four polychemotherapy cycles, allogeneic BMT or autologous PBSCT were given as consolidation.
RESULTS: Median age was 38 years (range, 17 to 65). Of 61 patients, 43 (70.5%) achieved CR and 6 (9.8%) died of early complications. The Kaplan-Meier estimated overall survival rate was 51.8±7.7%, 43.1±8.5% and 29.6±8.8% at 1 year, 2 year and 3 year respectively, and the disease free survival rate was 58.4±9.7%, 43.3±10.4% and 24.0±12.2% at 1 year, 2 year and 3 year, respectively. Unfavorable prognostic variables for achieving CR were age >55 years (p=0.006), FAB subtypes (p=0.005) and poor risk
cytogenetic abnormalities (p=0.021), and FAB subtypes for overall survival (p=0.0064).
CONCLUSION: IDA/BH-AC combination chemotherapy is an effective and well-tolerated regimen for induction treatment of AML.
Keywords Acute myelogenous leukemia; Combination chemotherapy; Idarubicin; BH-AC; Prognostic factor;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 2000; 35(2): 109-116
Published online June 30, 2000
Copyright © The Korean Society of Hematology.
급성 골수성 백혈병 환자에서 Idarubicin/BH-AC 복합관해유도요법의 치료 효과 및 예후 분석
이제중, 정익주, 양덕환, 조상희, 양태영, 박형천, 박무림, 김형준
전남대학교 의과대학 내과학교실
Therapeutic Effect and Prognostic Analysis of Induction Chemotherapy with Idarubicin/BH-AC in Acute Myelogenous Leukemia
Je Jung Lee, Ik Joo Chung, Duc Hwan Yang, Sang Hee Cho, Tae Young Yang, Hyeong Cheon Park, Moo Rim Park, Hyeoung Joon Kim
Department of Internal Medicine, Chonnam National University Medical School, kwangju, Korea
Abstract
BACKGROUND: We have analyzed the outcome and prognostic factors for 61 patients with acute myelogenous leukemia (AML) who were treated with idarubicin(IDA)/N 4-behenoyl-1-β-D-arabinofuranosylcytosine(BH-AC) regimen at Chonnam National University Hospital between April 1994 and December 1998.
METHODS: Fifty-six patients with newly diagnosed AML and 5 patients failed by IDA/ara-C were eligible to analysis. Remission induction chemotherapy consisted of IDA (12 mg/㎡/day IV over 30 minutes on days 1∼3) and BH-AC (age≤40 years : 300 mg/㎡/day IV over 4 hours on days 1∼7 ; age>40 years : 200 mg/㎡/day). After achievement of a complete remission (CR), four polychemotherapy cycles, allogeneic BMT or autologous PBSCT were given as consolidation.
RESULTS: Median age was 38 years (range, 17 to 65). Of 61 patients, 43 (70.5%) achieved CR and 6 (9.8%) died of early complications. The Kaplan-Meier estimated overall survival rate was 51.8±7.7%, 43.1±8.5% and 29.6±8.8% at 1 year, 2 year and 3 year respectively, and the disease free survival rate was 58.4±9.7%, 43.3±10.4% and 24.0±12.2% at 1 year, 2 year and 3 year, respectively. Unfavorable prognostic variables for achieving CR were age >55 years (p=0.006), FAB subtypes (p=0.005) and poor risk
cytogenetic abnormalities (p=0.021), and FAB subtypes for overall survival (p=0.0064).
CONCLUSION: IDA/BH-AC combination chemotherapy is an effective and well-tolerated regimen for induction treatment of AML.
Keywords: Acute myelogenous leukemia, Combination chemotherapy, Idarubicin, BH-AC, Prognostic factor,
Previous Article
